Bladoo
A first-in-class beta-3 adrenergic agonist for the effective management of Overactive Bladder (OAB) — providing relief from urgency, frequency, and urge urinary incontinence.
What is Bladoo?
Bladoo is a branded pharmaceutical product by Inspiron Scientific Pvt. Ltd. containing Mirabegron — a first-in-class beta-3 adrenergic receptor agonist available in 25mg and 50mg extended-release tablet formulations. It represents a novel, non-anticholinergic approach to managing Overactive Bladder (OAB).
Unlike traditional anticholinergic medications, Bladoo works by activating beta-3 adrenergic receptors in the detrusor smooth muscle of the bladder. This relaxes the bladder during the filling (storage) phase, increasing bladder capacity and reducing the symptoms of urgency, frequency, and urge urinary incontinence — without the common anticholinergic side effects like dry mouth and constipation.
Detailed Product Information
Comprehensive information about Bladoo 25mg & 50mg — from composition and mechanism of action to dosage, clinical benefits, and storage guidelines.
Bladoo 25mg
Bladoo 25mg contains Mirabegron 25mg as an extended-release tablet. This is the recommended starting dose for patients initiating Mirabegron therapy. It is also the preferred dose for patients with moderate hepatic impairment (Child-Pugh Class B) or severe renal impairment (GFR 15–29 mL/min). The 25mg dose offers a gentler introduction to beta-3 agonist therapy while still providing meaningful OAB symptom relief.
Key Features — 25mg
- Recommended starting dose for initial OAB therapy
- Suitable for dose-sensitive patients and elderly
- Preferred dose for moderate hepatic impairment
- Maximum recommended dose for severe renal impairment
- Can be taken with or without food
- Extended-release formulation for 24-hour coverage
- May be uptitrated to 50mg based on efficacy and tolerability
Bladoo 50mg
Bladoo 50mg contains Mirabegron 50mg as an extended-release tablet. This is the standard maintenance dose and provides optimal efficacy for OAB symptom management. Clinical studies have demonstrated that 50mg provides the best balance of efficacy and tolerability, with significant reductions in micturition frequency, urgency episodes, and urge incontinence episodes compared to placebo.
Key Features — 50mg
- Standard maintenance dose for optimal OAB management
- Proven significant reduction in urgency and frequency
- Superior efficacy in reducing urge incontinence episodes
- Extended-release for sustained 24-hour bladder control
- Can be taken with or without food
- No dose adjustment needed for mild-moderate renal impairment
- Well-tolerated with low discontinuation rates in clinical trials
• Mirabegron 25mg (Bladoo 25)
• Mirabegron 50mg (Bladoo 50)
Dosage Form: Extended-Release Film-Coated Tablets
Route: Oral Administration
Category: Beta-3 Adrenergic Receptor Agonist
Marketed by: Inspiron Scientific Pvt. Ltd.
During the storage/filling phase, activation of these receptors relaxes the detrusor muscle, increasing bladder capacity and reducing involuntary bladder contractions. This mechanism is fundamentally different from anticholinergics, resulting in fewer anticholinergic side effects such as dry mouth, constipation, and cognitive impairment.
- Urge urinary incontinence
- Urinary urgency
- Increased urinary frequency (≥8 micturitions/day)
- Nocturia associated with OAB
- Patients intolerant to anticholinergic therapy
- Patients with inadequate response to anticholinergics
- Novel mechanism — First-in-class beta-3 agonist, not an anticholinergic
- Significant reduction in urgency episodes, frequency, and incontinence
- Fewer side effects — Lower incidence of dry mouth and constipation vs. anticholinergics
- Increased bladder capacity — Relaxes detrusor during storage phase
- Sustained efficacy with extended-release formulation (once daily dosing)
- Well-tolerated in long-term studies with low discontinuation rates
Maintenance Dose: May be increased to 50mg once daily (Bladoo 50) based on individual efficacy and tolerability, typically after 8 weeks.
Administration: Take with or without food. Swallow whole with water — do not crush, chew, or divide the tablet (extended-release formulation).
Special Populations: Max 25mg/day in severe renal impairment (GFR 15–29) or moderate hepatic impairment (Child-Pugh B). Not recommended in severe hepatic impairment or end-stage renal disease.
Packaging: Available in alu-alu blister packs for optimal protection of the extended-release tablets.
Shelf Life: As mentioned on the pack. Do not use after the expiry date.
Special Note: Do not split or crush tablets. The extended-release coating is essential for proper drug delivery and consistent plasma levels over 24 hours.
Understanding Overactive Bladder (OAB)
Overactive Bladder (OAB) is a common urological condition characterized by a sudden, compelling urge to urinate that is difficult to control. It occurs when the detrusor muscle of the bladder contracts involuntarily during the filling phase, even when the bladder isn't full, leading to urgency, frequency, and often involuntary urine leakage.
OAB is not a disease but a syndrome of symptoms that can significantly impact quality of life, causing social embarrassment, anxiety, depression, and sleep disturbances. It affects both men and women, with prevalence increasing with age. Bladoo (Mirabegron) offers a modern therapeutic approach by relaxing the bladder muscle through beta-3 receptor activation.
Common Symptoms of OAB
Recognizing these symptoms early can lead to timely treatment and significantly improved quality of life. Consult your doctor if you experience:
How Bladoo Helps
Bladoo (Mirabegron) works through a unique beta-3 receptor activation pathway to deliver effective OAB symptom relief without anticholinergic side effects.
- Take Bladoo only as prescribed by your doctor — do not self-medicate
- Can be taken with or without food; swallow tablet whole with water
- Do not crush, chew, or break the extended-release tablet
- Blood pressure should be monitored before and during treatment
- Contraindicated in patients with severe uncontrolled hypertension (systolic ≥180 or diastolic ≥110 mmHg)
- Use with caution in patients with bladder outlet obstruction or taking antimuscarinic medications
- May cause urinary tract infection, nasopharyngitis, or headache as common side effects
- Inform your doctor about all medications, especially CYP2D6 substrates (e.g., metoprolol, desipramine)
- If symptoms worsen or do not improve after 8 weeks of treatment
- If you experience blood in urine or painful urination
- If you develop signs of urinary retention (inability to empty bladder)
- If you have severe uncontrolled high blood pressure
- If you have severe liver or kidney disease
- If you experience allergic reactions such as rash, swelling, or difficulty breathing
- If you are pregnant, planning pregnancy, or breastfeeding
- Before starting any new medications alongside Bladoo
Discover Inspiron Scientific's complete range of pharmaceutical products.
Ready to Partner
With Inspiron Scientific?
Whether you're a healthcare provider seeking quality pharmaceutical products, a distributor exploring partnership opportunities, or a professional looking to join our team — we'd love to hear from you.
Connect With Inspiron Scientific
Our team is available to discuss how Inspiron Scientific can support your healthcare needs. Reach out today.
AIMS, Ponekara (P.O.),
PIN – 682041, Kochi, Kerala
Door No. 37/558-P, Q, R, N,
Near Govt. Ayurveda Hospital,
Mullampara, Manjeri (P.O.) – 676121, Kerala
9:00 AM – 7:00 PM IST
Enquiry Form
Fill out the form below and our team will contact you promptly.
Our Quality Commitment
At Inspiron Scientific, quality is non-negotiable. Every product in our portfolio is sourced from WHO-GMP certified manufacturing partners and undergoes rigorous quality assurance processes. We stand behind the safety, efficacy, and consistency of every medicine we deliver.